Shoreline Biosciences Finds $140M
socalTECH
NOVEMBER 2, 2021
San Diego-based Shoreline Biosciences, a developer of cell immunotherapies for treating solid tumors and hematologic malignancies, has raised $140M in a financing round, the company said today. The company said that Frank Yu, Founder, CEO and CIO of Ally Bridge Group, joined the company's board of directors as part of the funding.
Let's personalize your content